Celltrion
↗Incheon, South Korea
Celltrion is a leading South Korean biopharmaceutical company that pioneered the global biosimilar market. It is primarily known for developing the world's first monoclonal antibody biosimilar, Remsima. The company specializes in the research, development, and manufacture of biological medicines for autoimmune diseases, oncology, and other therapeutic areas.
In late 2023, Celltrion successfully merged with Celltrion Healthcare to streamline its distribution and R&D operations. The company is currently transitioning from a biosimilar-focused player to an innovative drug developer, investing heavily in next-generation modalities such as Antibody-Drug Conjugates (ADCs), multispecific antibodies, and oral biologics.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Biosimilars & Innovative Therapeutics
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$2.5B - $3.1B
Founded:2002
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Temasek Holdings (Historically), Public Markets
STOCK
Exchange:KRX
Ticker:068270
Market Cap:$25B - $30B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Zymfentra/Remsima SC)
Modalities:mAb, Biosimilar, ADC, Multispecific antibody, Oral Biologics, Microbiota
Active Trials:123
Trial Phases:Phase 1: 15 | Phase 2: 10 | Phase 3: 25 | Phase 4: 5
FDA Approvals:8
EMA Approvals:9
CORPORATE STRUCTURE
Subsidiaries:Celltrion Pharm, Celltrion Skincure, Celltrion Branchburg (USA)
Key Partnerships:Pfizer (Inflectra distribution), Teva (Truxima/Herzuma distribution in US), MustBio (Triple fusion immunotherapy co-development), Eli Lilly (CMO agreement for $473M)
COMPETITION
Position:Leader
Competitors:Samsung Bioepis, Sandoz, Amgen, Organon, Biocon
LEADERSHIP
Key Executives:
Seo Jung-jin - Chairman of Celltrion Group
Seo Jin-seok - Co-Chairman & CEO
Scientific Founders:Seo Jung-jin
Board Members:Woosung Kee (Co-CEO), Hyoungki Kim (Co-CEO), Keun-young Kim (Independent Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Celltrion. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.